Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Jong, G. J.
Right arrow Articles by Meerwaldt, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Jong, G. J.
Right arrow Articles by Meerwaldt, J. D.
NEUROLOGY 1984;34:1507
© 1984 American Academy of Neurology
Brief Communication

Response variations in the treatment of Parkinson's disease

G. J. de Jong and J. D. Meerwaldt

From the Department of Neurology, University Hospital Rotterdam, The Netherlands.

The problems of long-term levodopa therapy tend to occur earlier if levodopa is combined from the start with a decarboxylase inhibitor. We conducted a retrospective study of 123 patients. Among patients treated with levodopa without a decarboxylase inhibitor, only 25% had response variations (end-of-dose deterioration, on-off response fluctuation) after 6 years of treatment. Among patients treated with both levodopa and a decarboxylase inhibitor, 90% showed response variations after 6 years of therapy.

Address correspondence and reprint requests to Dr. Meerwaldt, Department of Neurology, University Hospital Rotterdam "Dijkzigt", 40 Dr Molewaterplein, 3015 GD Rotterdam, The Netherlands.

Accepted for publication March 8, 1984.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1984 by AAN Enterprises, Inc.